5 Key Takeaways

• 1

  OCU410 is an investigational gene therapy for geographic atrophy, presented by Dr. Arshad M. Khanani at the 2026 ASRS meeting.

• 2

  The phase 2 ArMaDa study involved two dose cohorts of OCU410 and a control arm, each with 17 patients.

• 3

  A 34% reduction in geographic atrophy growth was observed in the medium-dose cohort compared to the control.

• 4

  OCU410 was well tolerated, with no reported cases of retinal vasculitis, occlusive retinal vasculitis, or endophthalmitis.

• 5

  A phase 3 program for OCU410 is expected to begin later this year.